Why the study?
Shenmai injection is commonly used to control doxorubicin-induced cardiotoxicity, but its anti-cardiotoxicity mechanism remains unknown.
Does Shenmai injection prevent doxorubicin-induced cardiotoxicity in preclinical models?
Population
C57BL/6 mice and H9c2 cardiomyocytes
Comparison
Shenmai injection vs controls in doxorubicin-induced myocardial injury
Design
In vivo animal and in vitro cellular experimental study
Authors
Loading...
Supports SMI testing in doxorubicin models; leaves open clinical translation pending human trials.
Does Shenmai injection prevent doxorubicin-induced cardiotoxicity in preclinical models?
Shenmai injection demonstrates cardioprotective effects against doxorubicin-induced cardiotoxicity in preclinical models by maintaining mitochondrial homeostasis via AMPK and PI3K/Akt/GSK-3β pathways.
Li et al. (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: